Home
About
Overview
Sharing Data
ORCID
Help
History (22)
Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.
Resuscitation for Donation After Brain Death: Respecting Autonomy and Maximizing Utility.
Broadening Access to Continuous Glucose Monitoring for Patients With Type 2 Diabetes.
Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy.
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
See All 22 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2018 02 08; 378(6):518-528.
View in:
PubMed
subject areas
Adult
Aged
Antibodies, Monoclonal
Antineoplastic Combined Chemotherapy Protocols
Bortezomib
Disease-Free Survival
Female
Follow-Up Studies
Humans
Intention to Treat Analysis
Kaplan-Meier Estimate
Male
Melphalan
Middle Aged
Multiple Myeloma
Prednisone
Survival Rate
authors with profiles
Andrzej Jakubowiak